Female sex as a thromboembolic risk factor in the era of nonvitamin K antagonist oral anticoagulants
M Gallù, G Marrone, JM Legramante… - Cardiovascular …, 2020 - Wiley Online Library
Sex‐specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
M Gallù, G Marrone, JM Legramante… - Cardiovascular …, 2020 - pubmed.ncbi.nlm.nih.gov
Sex-specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants.
M Gallu, G Marrone, JM Legramante… - Cardiovascular …, 2020 - go.gale.com
Sex-specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
M Gallù, G Marrone, JM Legramante… - Cardiovascular …, 2020 - search.proquest.com
Sex-specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants.
M Gallù, G Marrone, JM Legramante… - Cardiovascular …, 2020 - search.ebscohost.com
Sex-specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
[HTML][HTML] Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
M Gallù, G Marrone, JM Legramante… - Cardiovascular …, 2020 - ncbi.nlm.nih.gov
Sex-specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants.
M Gallù, G Marrone, JM Legramante… - Cardiovascular …, 2020 - europepmc.org
Sex-specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
[PDF][PDF] Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
M Gallù, G Marrone, JM Legramante, A De Lorenzo… - 2020 - pdfs.semanticscholar.org
Sex-specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
Female sex as a thromboembolic risk factor in the era of nonvitamin K antagonist oral anticoagulants
M Gallù, G Marrone, J Legramante… - CARDIOVASCULAR …, 2020 - art.torvergata.it
Sex-specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants.
M Gallù, G Marrone, JM Legramante… - Cardiovascular …, 2020 - europepmc.org
Sex-specific differences have been definitively demonstrated in cardiovascular (CV)
diseases. These differences can also impact on the effects of CV therapies. Female sex is …
diseases. These differences can also impact on the effects of CV therapies. Female sex is …